BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pietrobon V, Marincola FM. Hypoxia and the phenomenon of immune exclusion. J Transl Med 2021;19:9. [PMID: 33407613 DOI: 10.1186/s12967-020-02667-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Yang F, Peng X, Li X, Luo N, Zhu W, Fu M, Li Q, Hu G. Hypoxia Constructing the Prognostic Model of Colorectal Adenocarcinoma and Related to the Immune Microenvironment. Front Cell Dev Biol 2021;9:665364. [PMID: 33959617 DOI: 10.3389/fcell.2021.665364] [Reference Citation Analysis]
2 Pietrobon V, Todd LA, Goswami A, Stefanson O, Yang Z, Marincola F. Improving CAR T-Cell Persistence. Int J Mol Sci 2021;22:10828. [PMID: 34639168 DOI: 10.3390/ijms221910828] [Reference Citation Analysis]
3 Cui H, Su Y, Wei W, Xu F, Gao J, Zhang W. How Microalgae is Effective in Oxygen Deficiency Aggravated Diseases? A Comprehensive Review of Literature. Int J Nanomedicine 2022;17:3101-22. [PMID: 35874112 DOI: 10.2147/IJN.S368763] [Reference Citation Analysis]
4 Abou Khouzam R, Zaarour RF, Brodaczewska K, Azakir B, Venkatesh GH, Thiery J, Terry S, Chouaib S. The Effect of Hypoxia and Hypoxia-Associated Pathways in the Regulation of Antitumor Response: Friends or Foes? Front Immunol 2022;13:828875. [PMID: 35211123 DOI: 10.3389/fimmu.2022.828875] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
5 Lane B, Khan MT, Choudhury A, Salem A, West CML. Development and validation of a hypoxia-associated signature for lung adenocarcinoma. Sci Rep 2022;12:1290. [PMID: 35079065 DOI: 10.1038/s41598-022-05385-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zhang X, Fan C, Li J, Zhang X, Li Q, Wang Z. Transcriptome Analysis of Crassostrea sikamea (♀) × Crassostrea gigas (♂) Hybrids Under Hypoxia in Occluded Water. Front Mar Sci 2022;9:851098. [DOI: 10.3389/fmars.2022.851098] [Reference Citation Analysis]
7 Wu M, Niu X, Zhang R, Ping Xu Z. Two-dimensional nanomaterials for tumor microenvironment modulation and anticancer therapy. Adv Drug Deliv Rev 2022;187:114360. [PMID: 35636568 DOI: 10.1016/j.addr.2022.114360] [Reference Citation Analysis]
8 Cluff E, Magdaleno CC, Fernandez E, House T, Swaminathan S, Varadaraj A, Rajasekaran N. Hypoxia-inducible factor-1 alpha expression is induced by IL-2 via the PI3K/mTOR pathway in hypoxic NK cells and supports effector functions in NKL cells and ex vivo expanded NK cells. Cancer Immunol Immunother 2022;71:1989-2005. [PMID: 34999917 DOI: 10.1007/s00262-021-03126-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Liberini V, Mariniello A, Righi L, Capozza M, Delcuratolo MD, Terreno E, Farsad M, Volante M, Novello S, Deandreis D. NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images. Cancers (Basel) 2021;13:4543. [PMID: 34572771 DOI: 10.3390/cancers13184543] [Reference Citation Analysis]
10 Sun T, Zhou M, Huang L. Chimeric antigen receptor engineered T-cell therapy for central nervous system lymphoma. Hematology and Oncology Discovery 2022;1. [DOI: 10.15212/hod-2022-0001] [Reference Citation Analysis]
11 Kim GB, Riley JL, Levine BL. Engineering T cells to survive and thrive in the hostile tumor microenvironment. Current Opinion in Biomedical Engineering 2022;21:100360. [DOI: 10.1016/j.cobme.2021.100360] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Vaupel P, Flood AB, Swartz HM. Oxygenation Status of Malignant Tumors vs. Normal Tissues: Critical Evaluation and Updated Data Source Based on Direct Measurements with pO2 Microsensors. Appl Magn Reson 2021;52:1451-79. [DOI: 10.1007/s00723-021-01383-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Yavartanoo M, Yi GS. Development and Validation of Tumor Immunogenicity Based Gene Signature for Skin Cancer Risk Stratification. Int J Mol Sci 2021;22:12025. [PMID: 34769455 DOI: 10.3390/ijms222112025] [Reference Citation Analysis]
14 Kim HJ, Ji YR, Lee YM. Crosstalk between angiogenesis and immune regulation in the tumor microenvironment. Arch Pharm Res 2022. [PMID: 35759090 DOI: 10.1007/s12272-022-01389-z] [Reference Citation Analysis]
15 Ma S, Zhao Y, Lee WC, Ong LT, Lee PL, Jiang Z, Oguz G, Niu Z, Liu M, Goh JY, Wang W, Bustos MA, Ehmsen S, Ramasamy A, Hoon DSB, Ditzel HJ, Tan EY, Chen Q, Yu Q. Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy. Nat Commun 2022;13:4118. [PMID: 35840558 DOI: 10.1038/s41467-022-31764-9] [Reference Citation Analysis]
16 Anduran E, Dubois LJ, Lambin P, Winum JY. Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 - 2021. Expert Opin Ther Pat 2021;:1-12. [PMID: 34241566 DOI: 10.1080/13543776.2021.1954617] [Reference Citation Analysis]
17 Mortezaee K, Majidpoor J. (Im)maturity in Tumor Ecosystem. Front Oncol 2022;11:813897. [DOI: 10.3389/fonc.2021.813897] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
18 Kopecka J, Salaroglio IC, Perez-Ruiz E, Sarmento-Ribeiro AB, Saponara S, De Las Rivas J, Riganti C. Hypoxia as a driver of resistance to immunotherapy. Drug Resist Updat 2021;:100787. [PMID: 34840068 DOI: 10.1016/j.drup.2021.100787] [Reference Citation Analysis]
19 Fu Z, Mowday AM, Smaill JB, Hermans IF, Patterson AV. Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy. Cells 2021;10:1006. [PMID: 33923305 DOI: 10.3390/cells10051006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Domènech M, Hernández A, Plaja A, Martínez-Balibrea E, Balañà C. Hypoxia: The Cornerstone of Glioblastoma. Int J Mol Sci 2021;22:12608. [PMID: 34830491 DOI: 10.3390/ijms222212608] [Reference Citation Analysis]
21 Zahedi-Amiri A, Malone K, Beug ST, Alain T, Yeganeh B. Autophagy in Tumor Immunity and Viral-Based Immunotherapeutic Approaches in Cancer. Cells 2021;10:2672. [PMID: 34685652 DOI: 10.3390/cells10102672] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Pereira M, Matuszewska K, Jamieson C, Petrik J. Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer. Front Endocrinol (Lausanne) 2021;12:772349. [PMID: 34867818 DOI: 10.3389/fendo.2021.772349] [Reference Citation Analysis]
23 Davis L, Recktenwald M, Hutt E, Fuller S, Briggs M, Goel A, Daringer N. Targeting HIF-2α in the Tumor Microenvironment: Redefining the Role of HIF-2α for Solid Cancer Therapy. Cancers (Basel) 2022;14:1259. [PMID: 35267567 DOI: 10.3390/cancers14051259] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Lappano R, Todd LA, Stanic M, Cai Q, Maggiolini M, Marincola F, Pietrobon V. Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment. Cancers 2022;14:539. [DOI: 10.3390/cancers14030539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]